Recurrent Breast Carcinoma Clinical Trial
Official title:
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
This phase II trial studies capecitabine and lapatinib ditosylate to see how well they work compared with capecitabine, lapatinib ditosylate, and cixutumumab in treating patients with previously treated HER2-positive stage IIIB-IV breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with cixutumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether capecitabine and lapatinib ditosylate are more effective when given with or without cixutumumab in treating breast cancer that has spread nearby or to other areas of the body.
PRIMARY OBJECTIVE:
I. To compare progression-free survival of HER2+ breast cancer patients randomized to receive
lapatinib ditosylate (lapatinib) and capecitabine +/- cixutumumab (IMC-A12).
SECONDARY OBJECTIVES:
I. To assess the safety and tolerability of lapatinib and capecitabine +/- IMC-A12 in HER2+
breast cancer patients.
II. To compare the overall survival time, time to treatment failure, confirmed tumor response
rate, and duration of response of lapatinib and capecitabine +/- IMC-A12 in HER2+ breast
cancer patients.
III. To assess patient compliance per treatment arm and to compare overall quality of life
and treatment side effects via patient-reported outcomes between treatment arms.
TRANSLATIONAL RESEARCH OBJECTIVES:
I. To determine the role of the following in predicting response to lapatinib and
capecitabine +/- IMC-A12:
Ia. Expression patterns and/or activation IGF- and ErbB family of receptors and signaling
molecules in formalin-fixed, paraffin-embedded breast tumor tissue.
Ib. Expression patterns and/or activation IGF- and ErbB receptors and signaling molecules in
circulating tumor cells from breast cancer patients.
Ic. Changes in expression patterns and/or activation IGF- and ErbB receptors and signaling
molecules following treatment with lapatinib and capecitabine +/- IMC-A12 in circulating
tumor cells from breast cancer patients.
Id. Expression patterns of IGF-1, IGF-II, insulin, growth hormone, and the IGF binding
proteins in the serum of breast cancer patients.
Ie. Changes in expression patterns of IGF-1, IGF-II, insulin, growth hormone, and the IGF
binding proteins in the serum of breast cancer patients.
II. Banking of paraffin-embedded tissue blocks/slides and blood products (i.e., serum,
plasma, and buffy coat) for future studies.
III. To assess the proportion of patients whose pathologic specimens were correctly diagnosed
as HER2 positive (according to 2007 American Society of Clinical Oncology [ASCO] College of
American Pathologist [CAP] guidelines) metastatic breast cancer.
OUTLINE: The first 10 patients enrolled on this study are assigned to cohort I (safety
analysis). All other patients are assigned to cohort II (randomized treatment).
COHORT I (SAFETY ANALYSIS, closed to accrual): Patients receive cixutumumab intravenously
(IV) over 1 hour on days 1, 8, and 15. Patients also receive capecitabine orally (PO) twice
daily (BID) on days 1-14 and lapatinib ditosylate PO once daily (QD) on days 1-21. Cycles
repeat every 21 days in the absence of disease progression or unacceptable toxicity.
COHORT II (RANDOMIZED TREATMENT): Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on
days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable
toxicity.
ARM B: Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also
receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months until disease
progression and then every 6 months for up to 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04052555 -
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04521764 -
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT00100750 -
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT03737695 -
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
|
||
Active, not recruiting |
NCT02595905 -
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
|
Phase 2 | |
Terminated |
NCT02149173 -
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
|
N/A | |
Completed |
NCT00390455 -
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
|
Phase 3 | |
Recruiting |
NCT03213041 -
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04529044 -
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
|
Phase 2 | |
Completed |
NCT00699491 -
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Terminated |
NCT01149356 -
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT01964924 -
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT00785291 -
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
|
Phase 3 | |
Terminated |
NCT02370264 -
Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer
|
N/A | |
Terminated |
NCT00998738 -
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
|
Phase 3 | |
Terminated |
NCT01071564 -
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Active, not recruiting |
NCT00520975 -
First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
|
Phase 3 | |
Completed |
NCT01251874 -
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03281902 -
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
|